MG 4101

Drug Profile

MG 4101

Alternative Names: Allogeneic natural killer cells – GC Pharma; Allogeneic NK cells; MG4101

Latest Information Update: 27 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Green Cross
  • Developer GC Pharma; Samsung Medical Center; Seoul National University Hospital
  • Class Antineoplastics; Natural killer cell therapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Hepatocellular carcinoma; Solid tumours
  • Phase I Lymphoma

Most Recent Events

  • 12 Jul 2018 Preclinical and planned clinical development is underway in Lymphoma in South Korea (Parenteral, Injection) (GC Pharma website; NCT03578198)
  • 06 Jul 2018 Seoul National University Bundang Hospital plans a phase II trial for indolent CD20-positive Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in South Korea (NCT03578198)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma in South Korea (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top